{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-23-000028","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.841572+00:00","generated_at":"2026-06-15T09:47:30.816569+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tarsus Q1 net loss $23.4M; cash $201.2M; TP-03 PDUFA Aug 25","bullets":["Net loss of $23.4M vs $20.2M in Q1 2022; revenue $2.5M from LianBio partnership.","Cash and marketable securities $201.2M as of March 31, 2023.","TP-03 (Demodex blepharitis) PDUFA date August 25, 2023; 93% of eye doctors would prescribe if approved.","Phase 2a trials ongoing for TP-04 (rosacea), TP-05 (Lyme prevention), and TP-03 (MGD).","Appointed Jeff Farrow as CFO and Chief Strategy Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-23-000028","json":"https://secwatch.observer/filing/0001819790-23-000028.json","markdown":"https://secwatch.observer/filing/0001819790-23-000028.md","text":"https://secwatch.observer/filing/0001819790-23-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979023000028/0001819790-23-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979023000028/tars-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:47:30.816569+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9ffa64000fa93a2425b43062a832d87bc06eeb61","claim":"Tarsus Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2023.","evidence_excerpt":"Tarsus Pharmaceuticals, Inc. (the “Company”) issued a press release, which, among other matters, sets forth the Company’s results of operations for the three months ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979023000028/0001819790-23-000028-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}